Skip to content
DataLookout
Menu

EMMA-CSNCT07751887

Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reopened
    • Trial sites expanded: 1 → 6 locations
  2. Notable Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Publications: details revised at 5 of 5 entries
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Rate of hematoma recurrence or treatment failure requiring surgical evacuation
Timeframe: Up to 90 days post-enrollment.

Secondary (1)

Incidence of periprocedural and postprocedural complications

Arms and interventions

Intervention ArmExperimental

Patients with chronic subdural hematoma (cSDH) who undergo middle meningeal artery embolization (MMAE). This procedure is performed either as a standalone treatment or as an adjunct to surgical evacuation, based on clinical indication.

Standard Care ArmNo intervention

Patients with chronic subdural hematoma (cSDH) who receive standard clinical care without undergoing middle meningeal artery embolization. This includes standard surgical evacuation (burr-hole craniostomy) or conservative management (observation, medication) based on current guidelines.

Devices: Middle Meningeal Artery Embolisation

Sites

6 sites in 1 country